Persistent Depressive Disorder Case Study

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R. psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry. 1994;51:8–19.[PubMed]

2. Weissman MM, Leaf PJ, Bruce ML, et al. The epidemiology of dysthymia in five communities: rate, risks, comorbidity, and treatment. Am J Psychiatry. 1988;145:815–19.[PubMed]

3. Markowitz JC, Moran ME, Kocsis JH, et al. Prevalence and comorbidity of dysthymic disorder among psychiatric outpatients. J Affect Disord. 1992;24:63–71.[PubMed]

4. Kitamura T, Fujiwara S, Iwara N, et al. Epidemiology of psychiatric disorders in Japan. In: Nakane Y, Radford M, editors. Images in Psychiatry. World Psychiatric Association; Japan: 1999. pp. 37–46.

5. Kawakami N, Takeshima T, Ono Y, et al. Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: preliminary finding from the World Mental Health Japan Survey 2002–2003. Psychiatry Clin Neurosci. 2005;59:441–52.[PubMed]

6. Mantani N, Hisanaga A, Kogure T, et al. Four cases of panic disorder successfully treated with Kampo (Japanese herbal) medicines: Kami-shoyo-san and Hange-koboku-to. Psychiatry Clin Neurosci. 2002;56:617–20.[PubMed]

7. Suzuki H, Inadomi JM, Hibi T. Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterol Motil. 2009;21:688–96.[PMC free article][PubMed]

8. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Asociation; 2000. p. 34. Text Revision.

9. Cassano GB, Benvenuti A, Miniati M, et al. The factor structure of lifetime depressive spectrum in patients with unipolar depression. J Affect Disord. 2009;115:87–99.[PMC free article][PubMed]

10. Terasawa K. Kampo (Japanese Oriental) Medicine. 1st edn. McIntyre; Tokyo: 1993.

11. Kogure T, sato N, Tahara E, et al. Assessment of effects of traditional herbal medicines on elderly patients with weakness using a self-controlled trials. Geriatrics Gerontology International. 2004;4:169–74.

12. Maruyama M, Tomita N, Iwasaki K, et al. Benefits of combining donepezil plus traditional Japanese herbal medicine on cognition and brain perfusion in Alzheimer‘s disease: a 12-week observer-blind, donepezil monotherapy controlled trial. J Am Geriatr Soc. 2006;54:869–71.[PubMed]

13. Wang Q, Iwasaki K, Suzuki T, et al. Potentiation of brain acetylcholine neurons by Kami-Untan-To (KUT) in aged mice: implications for a possible antidementia drug. Phytomedicine. 2000;7:253–58.[PubMed]

14. Nakagawasai O, Yamadera F, Iwasaki K, et al. Effect of kami-untan-to on the impairment of learning and memory induced by thiamine-deficient feeding in mice. Neuroscience. 2004;125:233–41.[PubMed]

15. Grünblatt E, Zehetmayer S, Bartl J, et al. Genetic risk factors and markers for Alzheimer’s disease and/or depression in the VITA study. J Psychiatr Res. 2009;43:298–308.[PubMed]

16. Smith YR, Minoshima S, Kuhl DE, et al. Effects of long-term hormone therapy on cholinergic synaptic concentrations in healthy postmenopausal women. J Clin Endocrinol Metab. 2001;86:679–84.[PubMed]

Since the classic descriptions, depression has been conceived as an episodic and recurrent illness. Depressive episodes with clear onset and offset and sharp contrast with one’s usual mood and behaviors are perhaps the most conspicuous feature of severe mood disorders. However, systematic studies of unselected samples have been telling a different story: a large proportion of individuals suffer from low mood, lack of interest, and other symptoms of depression chronically, with some fluctuations but no clearly demarcated episodes.1 Chronic patterns of symptoms are often under-recognized and undertreated in the community.2

This article provides an update on the diagnosis, causation, and treatment of chronic depressive problems, with a focus on the recently introduced diagnostic category of persistent depressive disorder (PDD).

Diagnosis

In DSM-III and DSM-IV, the protracted forms of depression have been conceptualized as dysthymia and by the chronic specifier of major depressive episodes. Dysthymia was characterized by milder symptoms not fully meeting criteria for MDD, but lasting 2 years or longer and meriting clinical attention because of the cumulative burden of long-standing symptoms. The symptomatic criteria for dysthymia differed in part from those for major depressive episode, with an emphasis on low self-esteem and hopelessness (Table 1).

In DSM-III and DSM-IV, dysthymia was trumped by MDD and was only diagnosed if the threshold for a major depressive episode was not met in the initial 2 years of symptoms. Major depressive episodes could be specified as chronic if the full criteria were continuously met for 2 years or longer.

The validity of dysthymia and its separation from MDD has been repeatedly discussed and questioned.3 When individuals with dysthymia were followed over long periods, it became clear that most of them also developed major depressive episodes, which suggests that dysthymia and major depressive episodes are phases of the same disorder rather than separate conditions.4 Dysthymia and MDD also run in the same families and respond to the same treatments. On the other hand, both dysthymia and chronic depression are associated with more impairment, comorbidity, and suicide risk than less persistent forms of depression.5

Chronic depression and dysthymia were merged into PDD in DSM-5. This new division of depressive disorders gives more weight to duration than to severity of symptoms. DSM-5 defines PDD on the basis of the set of symptoms for dysthymia, with the assumption that most individuals who meet the full symptoms for MDD also meet criteria for dysthymia. However, because of differences in symptomatic criteria, some individuals with chronic major depressive episodes will not meet the DSM-5 criteria for PDD.6

While the merger of dysthymia and chronic depression into PDD is well justified by their strong sequential comorbidity and similar implications for prognosis and treatment, several aspects of the new diagnosis are not well supported by evidence and may not be useful. Why do we need 2 different sets of symptomatic criteria for MDD and PDD? The reliability and validity of the dysthymia criteria has not been formally tested, prompting concerns about the value of the new diagnosis.3

The assumption that most individuals with chronic depression also fulfill the dysthymia criteria may not hold consistently enough—it creates a group of individuals who suffer from chronic depression but do not receive the PDD diagnosis. While it is undisputable that prolonged duration and nonepisodic character are relevant, there is no good justification for the 2-year cutoff. In fact, some of the work used to justify the validity of persistent depression is based on a duration of 1 year or longer.7 For clinical and prognostic purposes, it is important to emphasize that duration of depressive symptoms is important both below and above the 2-year mark regardless of whether the depression or dysthymia/PDD criteria are met.

References: 

1. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55:694-700.

2. Weissman MM, Klerman GL. The chronic depressive in the community: unrecognized and poorly treated. Compr Psychiatry. 1977;18:523-532.

3. Rhebergen D, Graham R. The re-labelling of dysthymic disorder to persistent depressive disorder in DSM-5: old wine in new bottles? Curr Opin Psychiatry. 2014;27:27-31.

4. Klein DN, Shankman SA, Rose S. Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am J Psychiatry. 2006;163:872-880.

5. Gilmer WS, Trivedi MH, Rush AJ, et al. Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. Acta Psychiatr Scand. 2005;112:425-433.

6. Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety. 2014;31:459-471.

7. Brown GW, Craig TK, Harris TO. Parental maltreatment and proximal risk factors using the Childhood Experience of Care & Abuse (CECA) instrument: a life-course study of adult chronic depression. J Affect Disord. 2008;110:222-233.

8. National Comorbidity Survey. http://www.hcp.med.harvard.edu/ncs. Accessed June 6, 2014.

9. Young AS, Klap R, Shoai R, Wells KB. Persistent depression and anxiety in the United States: prevalence and quality of care. Psychiatr Serv. 2008;
59:1391-1398.

10. Mondimore FM, Zandi PP, Mackinnon DF, et al. Familial aggregation of illness chronicity in recurrent, early-onset major depression pedigrees. Am J Psychiatry. 2006;163:1554-1560.

11. Klein DN, Riso LP, Donaldson SK, et al. Family study of early-onset dysthymia: mood and personality disorders in relatives of outpatients with dysthymia and episodic major depression and normal controls. Arch Gen Psychiatry. 1995;52:487-496.

12. Riso LP, Klein DN, Ferro T, et al. Understanding the comorbidity between early-onset dysthymia and cluster B personality disorders: a family study. Am J Psychiatry. 1996;153:900-906.

13. Røysamb E, Kendler KS, Tambs K, et al. The joint structure of DSM-IV Axis I and Axis II disorders. J Abnorm Psychol. 2011;120:198-209.

14. McGuffin P, Katz R, Watkins S, Rutherford J. A hospital-based twin register of the heritability of DSM-IV unipolar depression. Arch Gen Psychiatry. 1996;53:129-136.

15. Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis [published correction appears in Am J Psychiatry. 2012;169:439]. Am J Psychiatry. 2012;169:141-151.

16. Uher R, Caspi A, Houts R, et al. Serotonin transporter gene moderates childhood maltreatment’s effects on persistent but not single-episode depression: replications and implications for resolving inconsistent results. J Affect Disord. 2011;135:56-65.

17. Brown GW, Ban M, Craig TK, et al. Serotonin transporter length polymorphism, childhood maltreatment, and chronic depression: a specific gene-environment interaction. Depress Anxiety. 2013;30:5-13.

18. Uher R, Maier W, Hauser J, et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression [published correction appears in Br J Psychiatry. 2009;195:87]. Br J Psychiatry. 2009;194:252-259.

19. Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72:509-514.

20. von Wolff A, Hölzel LP, Westphal A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord. 2013;144:7-15.

21. Kriston L, von Wolff A, Westphal A, et al. Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety. 2014 Jan 21; [Epub ahead of print].

22. Stewart JW, McGrath PJ, Quitkin FM, et al. Chronic depression: response to placebo, imipramine, and phenelzine. J Clin Psychopharmacol. 1993;13:391-396.

23. Cuijpers P, Sijbrandij M, Koole SL, et al. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry. 2013;12:137-148.

24. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression [published correction appears in N Engl J Med. 2001;345:232]. N Engl J Med. 2000;342:1462-1470.

25. Kocsis JH, Gelenberg AJ, Rothbaum BO, et al. Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Arch Gen Psychiatry. 2009;66:1178-1188.

26. Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet. 2013;381:375-384.

27. Watkins KE, Hunter SB, Hepner KA, et al. An effectiveness trial of group cognitive behavioral therapy for patients with persistent depressive symptoms in substance abuse treatment. Arch Gen Psychiatry. 2011;68:577-584.

0 Replies to “Persistent Depressive Disorder Case Study”

Lascia un Commento

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *